Bashir A Zikria, Age 912101 Skycrest Dr APT 1, Walnut Creek, CA 94595

6564101, May 13, 2003

Aug 2, 2000

09/601585

Bashir A. Zikria - Norwood NJ

The Trustees of Columbia University in the City of New York - New York NY

A61N 136

607 40, 607133

An electrical device utilized to control the body weight of a medically overweight human being comprises of at least two electrical leads for implanting on the fundus of the stomach. An electrical generator/controller (pacemaker) generates and regulates the frequency and degree of electrical stimulation. The device can be used surgically, laproscopically, and/or endoscopically.

6668834, Dec 30, 2003

Nov 12, 1997

08/967562

Bashir Zikria - Norwood NJ, 07640

A61F 556

128848, 602902

An apparatus for preventing a sleeping person from snoring while permitting normal, comfortable sleep, having a flexible shaped body means designed to be worn in proximity to the users neck and beneath the users chin. Said shaped body means is designed to restrict the users forward cervical vertebral flexion, while permitting substantial flexibility of the neck in other directions to maximize comfort and permit normal sleep. The shaped body means has a first end and a second end restrained within proximity to a plane tangential to the rear of the users neck by a connecting device, yet displaced from immediate proximity to the back of the neck and head whereby said first and second ends of said body means do not encroach between said users neck and the associated bedding, thereby permitting normal repose. Said shaped body means is maintained in the appropriate orientation and proximity to the users neck and chin by attachment straps passing around the users neck and adjustablely attached by suitable fastening means.

7041655, May 9, 2006

Apr 22, 1997

08/837840

Bashir Zikria - Norwood NJ, US
Jemal D. Zikria - Norwood NJ, US

A61K 31/715
A61K 38/44

514 54, 514 59, 514 60, 514833, 424 944, 435 183

In accordance with the invention there is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The invention also provides a method for preventing the harmful effects of free radicals on cellular membranes and other organelles. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group consisting of hydroxyethyl starch and dextran of varying molecular sizes and at least one member of the group consisting of superoxide dismutase, glutathione peroxidase, catalase, hydroxyethyl rutoside, cyclic adenosine monophosphate and vitamin C. The compositions contain the macromolecules in a molecular size and concentration to effectively stabilize the capillary membrane. The stabilization effect is accomplished by a biophysical/biochemical process due to the adhesiveness and configuration of the macromolecules and because of their size.

2005013, Jun 23, 2005

Dec 18, 2003

10/737885

Bashir Zikria - Norwood NJ, US

A61F005/00

128845000, 128846000

A method of relieving neck, upper back, shoulder and arm pain due to injury, degenerative and inflammatory diseases, tumors, infections or congenital abnormalities of the vertebrae by having the subject having such pain wear a neck collar which is held securely around the neck and under the wearer's chin that permits lateral head motion but prevents downward flexion of the head.

2006012, Jun 15, 2006

Nov 17, 2005

11/280104

Bashir Zikria - Norwood NJ, US
J. Zikria - Old greenwich CT, US

A61K 38/17
A61K 31/7076
A61K 31/225
A61K 38/44
A61K 31/366
A61K 31/7034

424094400, 514012000, 514054000, 514059000, 514060000, 514047000, 514460000, 514548000

The present invention provides pharmaceutical compositions useful for the prevention and treatment of sepsis and other conditions such as stroke, reperfusion injury and heart attacks, containing 1) at least one macromolecular polysaccharide selected from the group consisting of hydroxyethyl starch, dextran, glycogen and mixtures thereof and 2) activated protein C. The compositions can further comprise at least one member selected from the group consisting of at least one antioxidant and/or at least one anti-infective. The present invention further provides methods of treating human subjects prior to or during sepsis and other conditions such as stroke, reperfusion injury and heart attacks to prevent leakage of macromolecules from capillary endothelial junctions and simultaneously prevent thrombosis and fibrin formation, reduce inflammation and improve microcirculation by intravenously administering to a subject in need of such treatment an effective amount of the said composition.

2006026, Nov 23, 2006

Aug 29, 2005

11/213303

Bashir Zikria - Norwood NJ, US
Jemal Zikria - Old Greenwich CT, US

A61K 38/48
A61K 38/40
A61K 38/22
A61K 38/54
A61K 48/00
A61K 31/7076
A61K 31/716
A61K 31/44
A61K 31/4172
A61K 31/353
A61K 31/715
A61K 31/385
A61K 31/355

514006000, 514012000, 514054000, 514059000, 514060000, 514044000, 514025000, 514027000, 514400000, 514456000, 514440000, 514458000, 514383000, 514358000, 514460000, 514047000, 514553000, 514763000, 514731000, 514651000

The present invention provides a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability and at the same time preventing the harmful effects of free radicals on capillaries and surrounding tissues. The method comprises administering to a subject an effective amount of a composition comprising at least one polysaccharide selected from the group of HES, glycogen and dextran of varying molecular sizes and at least one active agent selected from the group consisting of dehydroascorbic acid, von Willebrand Factor, hemoglobin, polysaccharide-conjugated hemoglobin, Cerovive, edaravone, dimethylthiourea, citicoline, poly(ADP-ribose) polymerase inhibitor, oxidant detoxification catalyst, adenosine 2a (A2a) receptor agonist, adenosine 1 (A1) receptor agonist, adenosine, inosine, xanthin oxidase inhibitor, polyethylene-glycol-modified albumin, adenosine triphosphate, histamine, taurine, simvastatin, atrial natriuretic peptide, sphinogosine 1-phosphate, apyrase, secretory leukocyte protease inhibitor, antithrombin III, adrenomedullin, intravenous immunologlobulin, sodium beta-aescin, Δ-1,2,3-triazoline and aminoalkylpyridine, aromatase inhibitors, and neuropilin-1, polynitroxyl albumin, α-phenyl-N-tert-butyl nitrone and the antioxidant subgroup consisting of tocopherols, tocotrienols, carotenoids, minerals and mineral-containing organic compounds, polyphenols, lipoic acids, transition metal ion-binding proteins, melatonin, hormones, polyamines, tamoxifen and its metabolites and propofol. The composition may further contain at least one member of the group of superoxide dismutase, glutathione peroxidase, catalase, hydroxyethyl rutoside, cyclic adenosine monophosphate and vitamin C. The compositions contain the macromolecules in a molecular size and concentration adequate to effectively stabilize the capillary membrane. The stabilization effect is accompanied by a biophysical and biochemical process due to the adhesiveness and configuration of the macromolecules, and because of their size. The treatment is benign as the macromolecules and active agents are non-toxic and biodegradable.

4994444, Feb 19, 1991

Jul 31, 1987

7/080403

Bashir A. Zikria - Norwood NJ

The Trustees of Columbia in the City of New York - New York NY

A61K 3100

514 60

The present invention provides compositions of matter and methods for treating a human subject to prevent leakage of serum albumin from capillary endothelial junctions during a period of increased capillary permeability. The method comprises administering to the human subject an effective capillary pore sealing amount of a macromolecule which is biodegradable, non-toxic, globular in shape, with a molecular weight range from about 100,000 daltons to about 1,000,000 daltons and a pharmaceutically acceptable carrier. The composition of matter comprises a fraction derived from hydroxyethyl starch.

5704358, Jan 6, 1998

Nov 22, 1994

8/344334

Bashir A. Zikria - Norwood NJ

The Trustees of Columbia University in the City of New York - New York NY

A61B 600

128654

This invention provides a method for determining the presence of capillary leak in a subject which comprises (a) introducing into the subject's circulation a pharmaceutically-acceptable solution comprising biodegradable, nontoxic, macromolecules, which macromolecules are smaller than endothelial gaps in capillaries of a subject having capillary leak, and each of which macromolecules is labeled with a detectable marker; (b) obtaining a sample of blood from the subject; (c) quantitatively measuring the detectable marker in the sample; (d) repeating steps (b) and (c) at a plurality of suitably spaced points in time; and (e) comparing the quantities of detectable marker so measured so as to ascertain a change in the quantity of detectable marker in the subject's circulation over time, the change being indicative of the presence of capillary leak, thereby determining the presence of capillary leak in the subject. The subject invention also provides an apparatus for displaying the quantity of detectable marker in a subject's circulation over time after introducing into the subject's circulation a pharmaceutically-acceptable solution comprising biodegradable, nontoxic macromolecules, which macromolecules are smaller than endothelial gaps of capillaries in a subject having capillary leak, and each of which macromolecules is labeled with a detectable marker, which apparatus comprises (a) means for obtaining samples of blood from the subject at a plurality of points in time; (b) means for quantitatively measuring the detectable marker in the sample obtained at each time point; and (c) means for displaying the quantities so measured. The aforementioned apparatus of the subject invention is useful for diagnosing capillary leak.